Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

17.5%

14 terminated/withdrawn out of 80 trials

Success Rate

81.3%

-5.2% vs industry average

Late-Stage Pipeline

16%

13 trials in Phase 3/4

Results Transparency

34%

21 of 61 completed trials have results

Key Signals

21 with results13 terminated

Enrollment Performance

Analytics

Phase 2

51(66.2%)

Phase 3

10(13.0%)

Phase 1

8(10.4%)

N/A

4(5.2%)

Phase 4

3(3.9%)

Early Phase 1

1(1.3%)

77Total

Phase 2(51)

Phase 3(10)

Phase 1(8)

N/A(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (80)

Showing 20 of 80 trials

NCT01652820Phase 2Completed

Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer

Role: collaborator

NCT00149175Completed

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Role: collaborator

NCT00118131Phase 2Terminated

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Role: collaborator

NCT00318903Phase 2Completed

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

Role: collaborator

NCT03004001Phase 2Terminated

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

Role: collaborator

NCT00193427Phase 2Completed

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Role: collaborator

NCT00210249Completed

Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment

Role: collaborator

NCT00193128Phase 1Completed

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Role: collaborator

NCT00193050Phase 2Completed

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Role: collaborator

NCT00210184Phase 2Completed

Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer

Role: collaborator

NCT00068341Phase 2Completed

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

Role: collaborator

NCT00822471Not ApplicableCompleted

Feasibility and Impact of "ABCs of Diabetes" Self-Management Education Program at an Urban Public Library

Role: collaborator

NCT00087035Phase 2Completed

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Role: collaborator

NCT00214058Phase 2Completed

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

Role: collaborator

NCT00318890Phase 1Completed

Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

Role: collaborator

NCT00390429Phase 1Completed

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Role: collaborator

NCT00426127Phase 2Terminated

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

Role: collaborator

NCT00280735Phase 2Completed

Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

Role: collaborator

NCT00170378Phase 4Completed

The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

Role: collaborator

NCT00279916Phase 3Completed

Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays

Role: collaborator